STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ALLO ALLOGENE THERAPEUTICS INCORPORATED StockScouter® Report

6

StockScouter® Score

ALLOGENE THERAPEUTICS INCORPORATED, a mid cap company in the healthcare sector, is expected to outperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • One or more less experienced analysts has modestly increased quarterly earnings estimates for ALLO. Positive/Neutral
  • The most recent quarterly earnings report was approximately equal to or higher than analysts’ consensus forecast, but is not suggestive of future returns. Neutral

 

Concerns

  • Short-term relative price momentum exhibits moderate weakness. Neutral/Negative
  • Shares are neither being accumulated heavily nor sold heavily by financial institutions. Neutral for a large company like ALLO

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be in favor, stocks will be , and healthcare stocks will be in favor.

Expected Risk/Return

Progress: 60% done.
Progress: 100% done.
Low
High

Core Model Grades

B
C
N/A
C

Previous Ratings

5
4
4